Previous close | 3.3000 |
Open | 3.6000 |
Bid | 2.5000 |
Ask | 4.3000 |
Strike | 50.00 |
Expiry date | 2024-01-19 |
Day's range | 3.3000 - 3.6000 |
Contract range | N/A |
Volume | |
Open interest | 210 |
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
French pharmaceutical giant Sanofi (NASDAQ: SNY) has long been a leader in the market for insulin. First, Sanofi was forced to decrease the price of its most prescribed insulin product after its only two real competitors in this area did something similar. Second, Sanofi announced the acquisition of Provention Bio, a biotech focusing on developing medicines to delay or prevent the onset of autoimmune diseases, such as Type 1a diabetes.
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.